



DERMTREAT APPOINTS KRISTINE PETERSON AS BOARD MEMBER

Copenhagen, Denmark – June 7th, 2017: Danish-based Dermtreat today announced the appointment of US-based Kristine Peterson as board member.

Ms. Peterson has a longstanding and successful career within the pharmaceutical industry including leading positions in the areas of strategic planning, commercialization and marketing for Bristol-Myers Squibb and Johnson & Johnson. Her most recent role was as CEO for the biotech company, Valeritas Inc., which included evolving the organization from an early stage company to a fully commercial operation. Prior to Valeritas, Ms. Peterson was Company Group Chair for Johnson & Johnson's Biotech Sector, where she was responsible for research, development, manufacturing, and commercialization of oncology, immunology, and other biotechnology therapies. Ms. Peterson is now working as strategic consultant and professional board member within the pharmaceutical and biotech industries.

The appointment to the Dermtreat board follows the successful closure of a USD 17.7 million Series A financing led by the US-based leading venture capital firm, Sofinnova, with the leading Nordic venture capital firms Novo Seeds and Lundbeckfonden Emerge in the syndicate.

Dermtreat has developed the Rivelin® patch – a breakthrough therapy for the treatment of mucosal diseases. Rivelin® is designed to deliver a pharmaceutical drug uni-directional to a mucosal surface – using an occlusive, bio-adhesive and bio-degradable patch, with a long adhesion time and a high flexibility, conforming to the mucosal surface.

Dermtreat plans to commence a clinical phase 2b study in Q4 2017 for the first candidate of the Rivelin® patch, targeting the unmet need of treating the auto-immune, inflammatory disease Oral Lichen Planus.

"We are excited by having attracted a strong candidate like Kristine Peterson to our board", says Jens Hansen, co-founder and CEO of Dermtreat. "We look forward to working with Kristine, and to benefiting from her very strong competencies within new product planning and commercialization".

Kristine Peterson will join Lars Ekman of Sofinnova, Stephan Christgau of Novo Seeds and Christian Elling of Lundbeckfonden Emerge, whom together with CEO Jens Hansen constitutes the board of Dermtreat ApS.

"I was introduced to Dermtreat by Lars Ekman and quickly saw a huge potential in the company. This novel technology covers a large unmet therapeutic need. The management team has shown an impressive ability to execute by bringing the first product through the pre-clinical phase," said Ms. Peterson. "I very much look forward to working with them, contributing to the strategic and commercial planning of Dermtreat's first product and of the further potential of the Rivelin® patch."

For additional information please contact:

Jens Hansen, PhD and Chief Executive Officer

Phone: (+45) 4050 5597

jh@rivelin.eu

www.rivelin.eu

**About Dermtreat**

Dermtreat ApS is a Danish-based, private, biopharmaceutical company focused on innovative approaches to the treatment of mucosal diseases. Dermtreat's lead product candidate is using its novel Rivelin® patch for the treatment of Oral Lichen Planus, a chronic condition that affect 1-2% of the population. The Rivelin® patch incorporates clobetasol propionate to treat OLP and is currently in Phase 1b, with commencement of Phase 2b planned for 4Q 2017.

Shareholders include Sofinnova Ventures, Lundbeckfonden Emerge, Novo Seeds and Welfare Tech Invest.

For additional information, please visit www.rivelin.eu.

About Oral Lichen Planus

Oral Lichen Planus is a chronic inflammatory condition that affects the mucous membranes of the mouth. OLP may appear as lesions in the mouth that may cause burning, pain and other discomfort. OLP is considered an autoimmune disorder and requires regular monitoring given patients may be at risk of developing mouth cancer in the affected areas. No approved treatment exists, with today's off-label treatment ranging from topic corticosteroids to laser ablation. It is estimated that OLP affects 1-2% of the population. *(Sources: Journal of Oral Maxillofacial Pathology 2011 May – August; Mayo Clinic; American Academy of Oral Medicine).*